8-Br-GTP (tetrasodium) (8-Bromoguanosine-5'-triphosphate (tetrasodium)) is a derivative of the energy substrate – GTP, for protein synthesis and gluconeogenesis. 8-Br-GTP (tetrasodium) inhibits the E. coli GTPase FtsZ with a Ki of 31.8 μM. 8-Br-GTP (tetrasodium) promotes the assembly of porcine brain microtubules.

isoGTP (Isoguanosine-5'-O-triphosphate) sodium is an isomer of guanosine 5'-triphosphate and a phosphorylated form of Crotonoside. isoGTP sodium inhibits transcription and induces T to C mutations in a reverse transcriptase assay. isoGTP sodium is promising for research of substrate specificity of phosphofructokinase and mutT homolog 1 (MTH1).

3′-Azido-2′,3′-dideoxy-CTP (AZddCTP) is a cytidine analog containing a 3-azido group. As a chain terminator, 3′-Azido-2′,3′-dideoxy-CTP can be incorporated into the nascent DNA chain by HIV reverse transcriptase. 3′-Azido-2′,3′-dideoxy-CTP terminates DNA synthesis due to the lack of a 3'-hydroxyl group, thereby inhibiting viral replication. 3′-Azido-2′,3′-dideoxy-CTP has IC50 values of 15.6 μM and 160.8 μM for WT HIV and AZTR HIV. 3′-Azido-2′,3′-dideoxy-CTP has antiviral activity.

3′-Azido-2′,3′-dideoxy-GTP (AZddGTP) is a selective telomerase inhibitor with a Ki value of 1.5 μM. 3′-Azido-2′,3′-dideoxy-GTP can be incorporated into the 3′-terminus of DNA by telomerase. 3′-Azido-2′,3′-dideoxy-GTP inhibits telomerase activity in HeLa cells in vitro.

isoGDP (trisodium) is a GDP isomer. isoGDP (trisodium) is a phosphorylated form of crotonoside. isoGDP (trisodium) is an inhibitor of mitochondrial ATPase with an IC50 of 3 μM.

(S)-STO021 is a highly selective, orally effective ERβ agonist. (S)-STO021 has a dual activity of inhibiting osteoclast activity and promoting osteoblast activity. (S)-STO021 can be used for research on osteoporosis.

8-ET-NAD+ (sodium) is the derivative of NAD+. 8-ET-NAD+ (sodium) can be used in screening of PARP1 gatekeeper mutations. 8-ET-NAD+ (sodium) can be studied in research on cancer.

Ganciclovir triphosphate (GCV-TP) disodium is a synthetic 2'-deoxyguanosine analog with activity in inhibiting human cytomegalovirus (CMV) replication. Ganciclovir triphosphate disodium is effective against CMV infection by binding to viral DNA polymerase and interfering with viral DNA synthesis. Ganciclovir triphosphate disodium has an IC50 of 0.01 μM against CMV strains from humans, monkeys, mice, and guinea pigs. Ganciclovir triphosphate disodium has also been used in gene-directed enzyme prodrug inhibition for cancer inhibition.

BMS-663749 is an HIV attachment inhibitor and phosphonooxymethyl prodrug of BMS-488043.

Scyllo-Inositol hexakisphosphate (Scyllo-IP6) sodium is a orthophosphate monoester found in lake sediments.

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid containing arachidonic acid at the sn-1 position. It is a precursor to 1-arachidonoyl glycerol (1-Monoarachidin). 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA binds to the LPA2/EDG4 receptor with an EC50 value of approximately 10 nM. It prevents TNF-α and IL-6 secretion in wild-type but not Lpa2-/- dendritic cells stimulated by LPS. It also decreases differentiation of HT-29 human colon carcinoma cells to goblet cells in the presence of sodium butyrate.

U-031 is an anti-tumor agent. U-031 can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. U-031 is commonly used in cancer research.

Squalamine (phosphate) (Compound ENT-01) is an orally active neuroprotective agent. Squalamine (phosphate) can displace α-Syn that is bound electrostatically to nerve cell membranes and prevent aggregation of α-Syn. Squalamine (phosphate) can be used for the research of neurological disease, such as Parkinson’s disease.

CGS 26303 is an endothelin-converting enzyme (ECE) inhibitor. CGS 26303 increases the expression of endothelin-converting enzyme-1 in endothelial cells. CGS 26303 attenuates cerebral vasospasm in a rabbit subarachnoid hemorrhage model. CGS 26303 improves birth survival and alleviates pulmonary hypoplasia in newborn rats in a rat model of congenital diaphragmatic hernia. CGS 26303 can be used for research on cardiovascular and cerebrovascular diseases and congenital diaphragmatic hernia.

K-757 is a GPR40 agonist with an EC50 of 2.1 ± 0.2 nM for human GPR40. K-757 exhibits a half-life of 1-11 h in Preclinical Species. K-757 stimulates GLP-1 secretion and has potential applications in bariatric research.

CGP-6809 is an orally active DNA inhibitor. CGP-6809 exhibits antitumor activity against various transplantable tumors in mice and rats, including melanoma, prostate cancer, and rectal cancer. CGP-6809 can be used in research on various cancers, including melanoma, prostate cancer, and rectal cancer.

EYE-003 is an orally active RPE65 inhibitor with an IC50 of 102 nM. EYE-003 regulates the visual cycle in mice by reducing 11-cis-retinal (11cRAL)) synthesis and increasing all-trans-retinyl esters (atREs). EYE-003 suppresses scotopic ERG b-wave amplitude and exerts protective effects against retinal degeneration in Abca4⁻/⁻ Rdh8⁻/⁻ mice (a STGD1 model) by reducing retinal autofluorescent puncta and preserving outer nuclear layer (ONL) thickness in a dose-dependent manner. EYE-003 can be used for the study of visual cycle-associated retinopathies, such as Stargardt disease type 1 (STGD1).

EYE-002 is a RPE65 inhibitor with an IC50 of 69 nM. EYE-002 promotes recovery of scotopic ERG a-/b-wave amplitudes. EYE-002 regulates the visual cycle in mice by reducing 11-cis-retinal (11cRAL)) synthesis and increasing all-trans-retinyl esters (atREs). EYE-002 exerts protective effects against photic retinal damage in mice. EYE-002 can be used for the study of visual cycle-associated retinopathies, such as Stargardt disease type 1 (STGD1).

A-72055 is a partial agonist of muscarinic receptors. A-72055 has binding activity to both M1 and M2 receptors, with Ki values of 32 nM and 30 nM, respectively. A-72055 can enhance cognitive function and improve learning and memory deficits. A-72055 has better security. A-72055 can be used for research on neurological disorders such as cognitive impairment.

(Methylamino)acetaldehyde is a linker. (Methylamino)acetaldehyde can be used in the synthesis of PROTACs, such as WZH-17-002.

VH032-cyclopropane-F-C4-CHO is an E3 ubiquitinase ligand-linker conjugate. VH032-cyclopropane-F-C4-CHO can be used to synthesize LC-MF-4.

CDK9 ligand-Linker Conjugate is a synthesized CDK9 ligand-linker conjugate that can be used for synthesis of dCDK9-202. dCDK9-202 is a potent CDK9 PROTAC degrader with anti-tumor activity.

(±)-Tuaimenal A ((+)-1) is a secondary metabolite and a derivative of Sesamol. (±)-Tuaimenal A has potent inhibitory activity against SARS-CoV-2 3CLpro with an IC50 of 33.3  μM. (±)-Tuaimenal A can be used for SARS-CoV-2 infection research.

CPD-2828 is an orally active and selective IRE1α inhibitor with an IC50 value of 1.2 μM. CPD-2828 is promising for research of endoplasmic reticulum stress-related diseases (e.g., cancer, neurodegenerative diseases).

ML121 is a selective and potent VIM-2 inhibitor with an IC50 of 54 nM and a Ki of 148 nM. ML121 shows inactive in IMP-1 and TEM-1 beta-lactamase assays. ML121 can potentiate the antibiotic activity of Imipenem in VIM-2 transformed E.coli.

BMS-347070 is an inhibitor of COX-2. BMS-347070 can be studied in research on Pluronic®-bassed nano-crystalline drug-polymer solid dispersions.

AVI-6451 is a novel orally effective SARS-CoV-2 Mac1 (IC50 = 28 nM) inhibitor. AVI-6451 can reduce viral load. AVI-6451 can be used for research on viral infections.

MM927 is a potent NVL inhibitor, with an IC50 of 0.053 μM. MM927 blocks 60S ribosomal subunit biogenesis in the nucleolus. MM927 induces half-mer polysomes, cell cycle arrest at G1/S and G2/M and apoptosis in cells. MM927 demonstrates antitumor efficacy in MOLM-13 AML and HCT116 CRC xenograft models. MM927 can be used for the study of cancers such as acute myeloid leukemia (AML) and colorectal cancer (CRC).

Besonprodil (CI-1041) is a potent NMDA antagonist.

Batoprazine (8-(1-piperazinyl)-2H-1-benzopyran-2-one)) is a 5-HT1A,1B receptor agonist. Batoprazine can replace the behavioral stimulus of eltoprazine in the two-lever operant discrimination test between eltoprazine and deionized water in rats (ED50: 0.20 mg/kg).